Amount Raised
$200 Million
Round Type
Post-IPO Equity
South San FranciscoBiotechnologyHealth CareTherapeuticsBiopharmaInvestors
Description
On December 9, 2025, Denali Therapeutics Inc entered into an underwriting agreement for a public offering of common stock and pre-funded warrants. The company is offering 9,142,857 shares of common stock at $17.50 each, along with pre-funded warrants for 2,285,714 shares. The underwriters will purchase the firm shares at $16.625 per share. This funding is aimed at advancing the company's therapeutic development initiatives.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as Denali Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Os Therapies raised $3.5M on January 14, 2026.
- Parabilis Medicines raised $305M (Series F) on January 8, 2026.
- CASI Pharmaceuticals raised $5M on December 27, 2025.
- Kodiak Sciences raised $160M (Post-IPO Equity) on December 18, 2025.
- Citius Oncology raised $18M (Funding Round) on December 9, 2025.
- BeyondSpring raised $2M (Funding Round) on November 21, 2025.
Who to call at Denali Therapeutics, and when
A new round usually means Denali Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Denali Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Denali Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Denali Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Denali Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Denali Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.